Rabbit TRIP12 Polyclonal Antibody | anti-TRIP12 antibody

TRIP12 Antibody (Center)

Cat. Num. AAA9216577

• Gene Names: TRIP12; ULF; TRIP-12
• Reactivity: Human; Predicted: Bovine, Mouse, Rat
• Applications: Western Blot
• Synonyms: TRIP12; Polyclonal Antibody; TRIP12 Antibody (Center); Purified Rabbit Polyclonal Antibody (Pab); E3 ubiquitin-protein ligase TRIP12; 632-; E3 ubiquitin-protein ligase for Arf; ULF; Thyroid receptor-interacting protein 12; TR-interacting protein 12; TRIP-12; KIAA0045; anti-TRIP12 antibody

• Host: Rabbit
• Reactivity: Human; Predicted: Bovine, Mouse, Rat
• Clonality: Polyclonal
• Isotype: Ig
• Specificity: This TRIP12 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 991-1023 amino acids from the Central region of human TRIP12.
• Form/Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
• Sequence Length: 2040

• Applicable Applications for anti-TRIP12 antibody: Western Blot (WB)
• Application Notes: WB ~~ 1:2000
• Antigen Source: Human
• Preparation and Storage: Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Western Blot (WB)

(Anti-TRIP12 Antibody (Center) at 1:2000 dilution + Caki-1 whole cell lysateLysates/proteins at 20 ug per lane.SecondaryGoat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution.Predicted band size : 220 kDaBlocking/Dilution buffer: 5% NFDM/TBST.)

Related Product Information for anti-TRIP12 antibody

E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardeless of the presence of lysine residues in target proteins. In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress. In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation. Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation. Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins. Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes.

References

Chen D.,et al.Nature 464:624-627(2010). Nomura N.,et al.DNA Res. 1:223-229(1994). Hillier L.W.,et al.Nature 434:724-731(2005). Lee J.W.,et al.Mol. Endocrinol. 9:243-254(1995). Olsen J.V.,et al.Cell 127:635-648(2006).

NCBI and Uniprot Product Information

• NCBI GI #: 545746335
• NCBI GeneID: 9320
• NCBI Accession #: NP_001271143.1
• NCBI GenBank Nucleotide #: NM_001284214.1
• UniProt Accession #: Q14669; Q14CA3; Q14CF1; Q15644; Q53R87; Q53TE7; D4HL82
• Molecular Weight: 220434
• NCBI Official Full Name: E3 ubiquitin-protein ligase TRIP12 isoform a
• NCBI Official Synonym Full Names: thyroid hormone receptor interactor 12
• NCBI Official Symbol: TRIP12
• NCBI Official Synonym Symbols: ULF; TRIP-12
• NCBI Protein Information: E3 ubiquitin-protein ligase TRIP12
• UniProt Protein Name: E3 ubiquitin-protein ligase TRIP12
• Protein Family: E3 ubiquitin-protein ligase
• UniProt Gene Name: TRIP12
• UniProt Synonym Gene Names: KIAA0045; ULF; ULF; TR-interacting protein 12; TRIP-12
• UniProt Entry Name: TRIPC_HUMAN

NCBI Description

TRIP12: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardeless of the presence of lysine residues in target proteins. In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress. In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation. Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation. Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins. Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes. Belongs to the UPL family. K-HECT subfamily. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: EC 6.3.2.19; Ubiquitin conjugating system; EC 6.3.2.-; Ubiquitin ligase; Nuclear receptor co-regulator; Ligase

Chromosomal Location of Human Ortholog: 2q36.3

Cellular Component: nucleoplasm; cytoplasm; nucleus

Molecular Function: protein binding; ubiquitin-protein ligase activity; thyroid hormone receptor binding; ligase activity

Biological Process: embryonic development; protein ubiquitination during ubiquitin-dependent protein catabolic process; DNA repair; response to DNA damage stimulus

Uniprot Description

TRIP12: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardeless of the presence of lysine residues in target proteins. In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress. In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation. Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation. Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins. Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes. Belongs to the UPL family. K-HECT subfamily. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Nuclear receptor co-regulator; EC 6.3.2.19; Ubiquitin conjugating system; Ligase; EC 6.3.2.-; Ubiquitin ligase

Chromosomal Location of Human Ortholog: 2q36.3

Cellular Component: nucleoplasm; nucleus

Molecular Function: ligase activity; protein binding; thyroid hormone receptor binding; ubiquitin-protein ligase activity

Biological Process: DNA repair; embryonic development; protein ubiquitination during ubiquitin-dependent protein catabolic process; response to DNA damage stimulus